Latest Idiopathic thrombocytopenic purpura Stories

2012-05-07 14:37:05

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP). In study results published online today in Blood, the Journal of the American Society of Hematology (ASH), investigators at Weill Cornell Medical College provide the very first long-term outcome data for...

2011-09-02 07:00:00

Trainer Lance Darling Pursues Extraordinary Athletic Feats in the Name of Children Who are Affected by ITP Bleeding Disorders; A Two-Day Fitness Fundraiser on September 16 & 17 to Benefit PDSA and Children with ITP Kansas City, MO (PRWEB) September 02, 2011 WHAT:    Athlete and trainer, Lance Darling, will conduct a record-breaking 30-hour marathon workout to raise funds and awareness for the Platelet Disorder Support Association (PDSA). Lance will be running 52.4...

2011-02-25 17:26:00

PHILADELPHIA, Feb. 25, 2011 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration (FDA) granted full approval for PROMACTA® (eltrombopag), an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. PROMACTA initially received FDA...

Word of the Day
  • Boughs or branches.
  • Warbling of birds in trees.